AB-BIOTICS: BIOTECHNOLOGY COMMITTED TO INNOVATION
Set up in April 2004 as a spin-off of the Universitat Autònoma de Barcelona (UAB), AB-BIOTICS (www.ab-biotics.com) is a leading Spanish company in the sector and the only Catalan biotechnology firm to be listed on the MAB (Alternative Investment Market).
AB-BIOTICS is located in the Eureka Building of the UAB, one of the largest scientific and technological complexes in southern Europe, and has laboratories in the Scientific and Technology Park of Girona University (UDG). The company’s business activities are focused on research and development and the protection and distribution of its own biotechnological solutions, which are above all, the only ones of their kind in the sector, that make a contribution to improving the health and wellbeing of people.
Thanks to its innovative philosophy and own know-how, AB-BIOTICS has a portfolio of avant-garde products which bring high added value to the healthcare, pharmaceutical and industrial sectors and not only result in benefits to health, but also contribute to reducing healthcare expenditure.
To achieve this, AB-BIOTICS is organised into four business divisions that are focused on different fields:
•R+D Partnering offers the pharmaceutical and food industries the comprehensive management of research projects, based on obtaining unique, patentable biotechnological solutions with high added value.
•Functional Ingredients develops probiotics and other nutraceuticals for the pharmaceutical and food sectors. These functional ingredients are useful for preventing and treating a wide range of conditions, ranging from cardiovascular disease to colic in infants, among others.
•AB-Genotyping focuses on the development of genetic analyses for conducting pharmacogenetic studies (the way in which patients respond to different treatments and medicines depending on their genetic heritage) in order to provide specialists with more information about the most effective therapies and most appropriate doses for each patient.
•AB-Therapeutics is a subsidiary that was set up in autumn 2009, for the purpose of discovering and developing truly innovative drugs for use in treating cancer, particularly lung cancer.